Age-Related DNA Methylation in Normal Kidney Tissue Identifies Epigenetic Cancer Risk Susceptibility Loci in the ANKRD34B and ZIC1 Genes

Jürgen Serth 1,*, Inga Peters 1, Bastian Hill 1, Tatjana Hübscher 1, Jörg Hennenlotter 2, Michael Klintschar 3 and Markus Antonius Kuczyk 1

1 Department of Urology and Urologic Oncology, Hannover Medical School, 30625 Hannover, Germany; peters.inga@mh-hannover.de (I.P.); bastian.hill@googlemail.com (B.H.); tatjanahuebscher@gmail.com (T.H.); kuczyk.markus@mh-hannover.de (M.A.K.)
2 Department of Urology, Eberhard Karls University of Tuebingen, 72076 Tuebingen, Germany; joerg.hennenlotter@med.uni-tuebingen.de
3 Department of Legal Medicine, Hannover Medical School, 30625 Hannover, Germany; klintschar.michael@mh-hannover.de
* Correspondence: serth.juergen@mh-hannover.de; Tel.: +49-511-532-6673

Abstract: Both age-dependent and age-independent alteration of DNA methylation in human tissues are functionally associated with the development of many malignant and non-malignant human diseases. TCGA-KIRC data were biometrically analyzed to identify new loci with age-dependent DNA methylation that may contribute to tumor risk in normal kidney tissue. ANKRD34B and ZIC1 were evaluated as candidate genes by pyrosequencing of 539 tissues, including 239 normal autopsy, 157 histopathologically tumor-adjacent normal, and 143 paired tumor kidney samples. All candidate CpG loci demonstrated a strong correlation between relative methylation levels and age (R = 0.70–0.88, p < 2 × 10^{-16}) and seven out of 10 loci were capable of predicting chronological age in normal kidney tissues, explaining 84% of the variance (R = 0.92). Moreover, significantly increased age-independent methylation was found for 9 out of 10 CpG loci in tumor-adjacent tissues, compared to normal autopsy tissues (p = 0.001–0.028). Comparing tumor and paired tumor-adjacent tissues revealed two patient clusters showing hypermethylation, one cluster without significant changes in methylation, and a smaller cluster demonstrating hypomethylation in the tumors (p < 1 × 10^{-10}). Taken together, our results show the presence of additional methylation risk factors besides age for renal cancer in normal kidney tissue. Concurrent tumor-specific hypermethylation suggests a subset of these loci are candidates for epigenetic renal cancer susceptibility.

Keywords: age-related methylation; age-dependent methylation; renal cell cancer; epigenetic; cancer susceptibility locus; cancer development; DNA-methylation; age signature; cancer diagnosis; cancer prediction

1. Introduction

Specific alterations in DNA methylation (DNAm) in human tissues and concurrent changes in the epigenetic regulation of gene expression are associated with a substantial number of malignant and non-malignant human diseases. Thus, elucidation of disease-specific DNAm patterns could improve the early detection, prognosis, and functional characterization of related pathogenic processes [1]. The epigenetic stem cell model of cancer connects epigenetic alterations, including DNAm, and stem cell gene silencing by Polycomb repressor complex 2 (PRC2) [2]. Accumulated hypermethylation and hypomethylation of Polycomb repressor target genes have been reported as hallmarks of malignant cellular transformation, explaining why age and the related number of cell divisions are the most important cancer risk factors (ibid). Moreover, interaction with genetic factors...
and external factors, including environmental and lifestyle effects, have been described to modify DNAme in a tissue- and gene-specific manner, providing a link between known cancer risk factors and molecular changes in cancer development [3].

Renal cell cancer (RCC) accounts for 3% and 5% of cancer diagnoses in men and woman, respectively, and approximately 25% of patients exhibit distant metastasis at the time the disease is detected [4]. Epidemiological analyses have identified age, obesity, and smoking as the most important risk factors for the development of the disease [5,6].

Epigenetic alterations have been reported to account for more than 60% of RCC risk [7], and a substantial number of reports have described an association of DNAme loci with the clinical stage, state of metastasis, prognosis, and therapeutic response of RCC [8].

Studies of DNAme at specific loci and the association with age or other RCC risk factors are relatively sparse, likely because analyses require normal human kidney samples from tissue donors with documented exposure to RCC risk factors. However, qualitative assessment of age-dependent methylation of selected genes in normal tissues has been described [9]. When comparing normal samples and tumor-adjacent normal (adN) samples, we found age-dependent DNAme of the SFRP1 loci, which was further increased in adN tissue samples, corresponding to odds of approximately 13 in interquartile analysis [10]. Recently, we reported age-dependent DNAme of the TBR1 loci [11] biometrically identified as a candidate region using a subset of adN data from the KIRC study branch of The Cancer Genome Atlas (TCGA) network study [12]. Interestingly, a comparison of cases and controls indicated an association of increased DNAme with tissue adiposity, providing a possible molecular link to the known epidemiological risk factor [11].

Here, we evaluated the Ankyrin Repeat Domain 34B (ANKRD34B) and Zic Family Member 1 (ZIC1) loci that were also biometrically identified as candidates in the KIRC-based adN analysis. The ANKRD34B protein is a cytosolic phosphoprotein described as being involved in the differentiation of mouse bone marrow cells [13]. The Human Protein Atlas (proteinatlas.org) reports high mRNA expression in prostate cancer and RCC, and immunopositivity has been detected in the cytoplasm of normal renal tubular cells, although RCCs tend to have a lack of signals [14]. Published data on the role of ANKRD34B in human disease is sparse. A biometrical study aiming to identify a biomarker signature for patients with Alzheimer’s disease reported a differentially methylated site in ANKRD34B [15], but increased mRNA expression has been reported in prostate carcinoma [16].

The ZIC1 protein belongs to the C2H2-type zinc finger family of proteins and exhibits transcriptional activator function with involvement in organogenesis of the central nervous system [17]. DNAme analyses of ZIC1 have been carried out to identify epigenetic silencing in colorectal cancer [18], gastric cancer [19], hepatocellular cancer [20,21], thyroid cancer [22], mesenchymal proliferation [23], malignant pleural mesothelioma [24], and myoblast development [25]; to detect precancerous alterations of the cervix [26–28]; to allow noninvasive detection of endometrial cancer [29] and gastric cancer [30,31]; to achieve clinical stratification of cervical cancer [32], anal cancer [33], and ovarian cancer [34]; and to assess the aggressiveness and progression of head and neck squamous cell carcinomas [35], high-grade non-invasive bladder cancer [36], gastric cancer [37], and ovarian cancer [38].

The ZIC1 loci was among the 2623 differentially methylated CpG sites annotated to 1405 genes in a meta study of epigenome-wide association studies (EWASs) comparing blood-derived DNA from smokers and non-smokers [39]. Interestingly, the ZIC1 locus was one of only three loci showing increased methylation in smokers in both blood and postmortem samples of the nucleus accumbens [40], indicating that ZIC1 methylation could be affected by lifestyle factors in various cell types. Both ANKRD34B and ZIC1 have been reported in a pan-cancer analysis to be targets of PRC2, with hypermethylated CGIs [41].

Here, we showed that DNAme of candidate loci ANKRD34B and ZIC1 strongly correlates with age and allows the estimation of chronological age with an acceptable error rate. Interestingly, a subgroup of tissues had significantly elevated levels of DNAme in adN samples that were not explained by age. In view of concurrent tumor-specific hyperme-
thylation, our results suggested the corresponding loci as candidates for epigenetic renal cancer susceptibility.

2. Results
2.1. Biometrical Analysis

Pearson correlation analysis of TCGA-KIRC methylation data and tissue donor age revealed coefficients of correlation of 0.66, 0.64, and 0.63 for the cg25316339, cg16181396, and cg218002332 loci, respectively (all \( p < 2 \times 10^{-16} \)). Inspection and measurement of control DNA and a pilot cohort and indicated that both candidate regions are technically amenable for evaluation by pyrosequencing (Figure 1; see Supplementary Figure S1 for primary data). The genomic positions of the assays and measurable CpG positions are presented in Table 1.

![Figure 1. Genomic organization of candidate regions of ANKRD34B (A) and ZIC1 (B) showing exons (thick orange rectangular boxes), genomic regions corresponding to UTRs (thinner orange boxes, only for ZIC1), CpG islands (CGI), all (CpG sites) and KIRC annotated CpG sites (KIRC), location of candidate sites (Candid.) and pyro sequencing assay (Assay).](image)

**Table 1.** Genomic positions of CpG sites in candidate regions and results of Pearson’s correlation analysis for association of methylation and age in normal autopsy renal tissues.

| Gene  | Chrom. | Pos.   | HM450K | R     | R²    | p.adj* | N  | Abbr |
|-------|--------|--------|--------|-------|-------|--------|----|------|
| ANKRD34B | chr5   | 79,866,347 | 0.75   | 0.56  | 0     | 214    | CG1|
|       | chr5   | 79,866,354 | 0.72   | 0.52  | 0     | 214    | CG2|
|       | chr5   | 79,866,359 | 0.74   | 0.55  | 0     | 214    | CG3|
|       | chr5   | 79,866,366 | 0.72   | 0.51  | 0     | 214    | CG4|
|       | chr5   | 79,866,368 cg21800232 | 0.70   | 0.49  | 0     | 214    | CG5|
|       | chr5   | 79,866,373 | 0.73   | 0.53  | 0     | 214    | CG6|
|       | chr5   | 79,866,379 cg25316339 | 0.61   | 0.37  | 0     | 214    | CG7|
|       | chr3   | 147,126,196 | 0.70   | 0.49  | 0     | 214    | CG1|
|       | chr3   | 147,126,206 cg16181396 | 0.88   | 0.77  | 0     | 214    | CG2|
|       | chr3   | 147,126,218 | 0.74   | 0.55  | 0     | 214    | CG3|

Of note, all obtained \( p \)-values were below the lower calculation limit of \( 2 \times 10^{-16} \). Abbreviations: Chrom., chromosome; Pos., genomic position according to hg19 genome annotation; HM450K, Illumina methylation array CpG site annotation; R, Pearson’s correlation coefficient; p.adj*, Holms adjusted \( p \)-values for multiple testing; N, number of measurements; Abbr, CpG site designation used in manuscript and figures.
2.2. ANKRD34B and ZIC1 Loci Show a Strong Correlation with Age in Normal Kidney Tissues

Evaluation of candidate CpG loci methylation by pyrosequencing analysis of the normal tissue cohort demonstrated that 10 (100%) of the loci exhibited strong age-dependent methylation. Coefficients of correlation of 0.61–0.88 (all \( p < 2 \times 10^{-16} \)) were obtained in the Pearson correlation analysis, confirming all of the biometrical candidate loci (Table 1). Linear regression analysis revealed maximum increases in the methylation per year for the CG1 site of ANKRD34B (slope = 0.16; 95% CI 0.15–0.19) and the CG2 site of ZIC1 (slope = 0.26, 95% CI 0.24–0.28), corresponding to an expected 100-year lifetime-accumulated relative methylation change of 16% and 26% in normal tissues, respectively (Figure 2). Linear regression lines and confidence intervals (Figure 2, grey shaded areas) also indicate a significantly increased rate of methylation for the ZIC1 CG2 site compared to the ANKRD34B CG1 site in normal tissues.

![Figure 2](image-url)

**Figure 2.** Age dependent methylation of the ANKRD34B (blue rhombus shaped symbols and blue regression line) and ZIC1 (black solid circles and black regression line) CpG sites CG1 and CG2 exhibiting maximum R-values in Pearsons correlation analysis as specified in Table 1. Grey shaded areas indicate the 95% confidence intervals for regression lines.

Analysis of age-dependent methylation in adN tissues revealed significant relationships for 3 out of 10 CpG sites analyzed, resulting in \( R = 0.29 \) (ANKRD34B CG3, \( p = 0.02 \)), 0.36, and 0.51 (ZIC1 CG2 and CG3, respectively, \( p < 0.001 \)). No significant association of CpG candidate site methylation and age was found in tumor tissues (\( R = 0.08–0.18 \)).

2.3. Chronological Age Prediction of Normal Kidney Tissues

We recently reported the identification of age-related methylation of TBR1 CpG loci in kidney tissues [11]. One of these loci was described previously to be usable for methylation-based donor age determination via the measurement of saliva samples [42]. Whether ANKRD34B and ZIC1 loci contribute to age determination of kidney tissues was analyzed by random training, test cohorts, and linear regression, including a stepwise selection of variables and a 20-fold cross-validation. Methylation of 7 out of 10 (70%) loci, including CG1-CG3 from the ZIC1 region and CG1-CG4 from the ANKRD34B region, was identified as a significant model parameter to predict age in the unknown test cohort. A mean average error (MAE) of 6.9 years and an R value of 0.92, explaining 84% of the observed variance, were obtained for age prediction (Supplementary Figure S2).
2.4. Age-Independent Increase of ANKRD34B and ZIC1 Methylation in Normal High-Risk Tissues

DNAme is a known risk factor for tumorigenesis and measurably responds to various cancer-related lifestyle factors, such as age, inflammation, or contact with harmful substances. Therefore, we asked whether a difference in risk exposure other than age can be detected as altered mean group methylation in normal tissues with a different renal cancer risk. A comparison of 214 normal tissues with the average population risk for renal cancers and 157 (ANKRD34B) or 145 (ZIC1) adN tissue samples (i.e., cases with high cancer risk) revealed not only a clear age-dependent methylation pattern in normal and adN tissue, but also demonstrated methylation levels beyond the 99% prediction level of the linear regression, as defined by the analysis of low-risk normal tissues (Figure 3A, B: N and adN tissues). This effect was observed for the averaged methylation values of both ANKRD34B and ZIC1, and cannot be explained by age. Highly variable methylation independent of age was seen in tumor tissues (Figure 3A, B: T tissues).

Figure 3. Comparison of age-dependent average methylation observed for CG1-CG7 and CG1-CG3 sites in the ANKRD34B (A) and ZIC1 (B) candidate gene regions for normal (N), tumor adjacent normal (adN) and tumor (T) kidney tissue samples presenting methylation within 99% prediction channels (dashed lines) of linear regression (open black circles), above upper (solid red circles) and below lower boundaries (green circles).

CpG loci-specific comparisons of methylation in normal and adN tissues using logistic regression analysis revealed significant differences (Table 2, Figure 4). Odds ratios of 1.06–1.13 per 1% change in methylation were found for 9 out of 10 CpG sites located in two different gene regions (all p < 0.03, Bonferroni-adjusted for multiple testing). Moreover, logistic regression showed that methylation differences between tissues were not statis-
tically explained by the age or sex of tissue donors, which turned out to be insignificant parameters in the corresponding statistical model (Table 2).

Table 2. Results of CpG site specific logistic regression analysis for age and sex adjusted comparison of DNA-methylation in normal autopsy (N) and tumor adjacent normal kidney tissue samples (adN).

| CpG Site | Mean N | Mean adN | Diff. Mean | OR   | CI Low | CI High | p-Val | p-Val Bonf. | p-Val Age | p-Val Sex |
|----------|--------|----------|------------|-------|--------|---------|-------|------------|-----------|-----------|
| ANKRD34B |        |          |            |       |        |         |       |            |           |           |
| CG1      | 11.4   | 15.0     | 3.6        | 1.11  | 1.06   | 1.17    | 0.000 | 0.001      | 0.425     | 0.549     | 214 157   |
| CG2      | 9.9    | 13.1     | 3.2        | 1.13  | 1.07   | 1.21    | 0.000 | 0.001      | 0.492     | 0.576     | 214 157   |
| CG3      | 9.2    | 11.9     | 2.6        | 1.11  | 1.05   | 1.18    | 0.001 | 0.006      | 0.776     | 0.712     | 214 157   |
| CG4      | 6.8    | 9.1      | 2.3        | 1.10  | 1.04   | 1.18    | 0.002 | 0.016      | 0.932     | 0.690     | 214 157   |
| CG5      | 6.7    | 9.6      | 2.9        | 1.12  | 1.06   | 1.20    | 0.000 | 0.003      | 0.914     | 0.675     | 214 157   |
| CG6      | 11.6   | 13.8     | 2.2        | 1.07  | 1.02   | 1.12    | 0.004 | 0.029      | 0.814     | 0.693     | 214 157   |
| CG7      | 7.3    | 9.2      | 1.9        | 1.08  | 1.03   | 1.16    | 0.010 | 0.071      | 0.446     | 0.815     | 214 157   |
| ZIC1     |        |          |            |       |        |         |       |            |           |           |
| CG1      | 14.7   | 16.8     | 2.1        | 1.11  | 1.04   | 1.20    | 0.006 | 0.017      | 0.981     | 0.822     | 214 145   |
| CG2      | 22.8   | 25.5     | 2.7        | 1.08  | 1.03   | 1.15    | 0.004 | 0.011      | 0.257     | 0.801     | 214 145   |
| CG3      | 18.8   | 20.7     | 2.0        | 1.09  | 1.03   | 1.17    | 0.005 | 0.015      | 0.871     | 0.968     | 214 145   |

CG annotation refers to genomic positions shown in Table 1. Abbreviations: Diff., difference; OR, odds ratio; CI low and high, lower and higher boundaries of 95% confidence interval; Bonf., Bonferroni adjustment for multiple testing.; n N, number of normal autopsy kidney tissues; n adN, number of tumor adjacent normal tissue samples.

Figure 4. Analysis of age-independent tumor risk for CG1-CG7 and CG1-CG3 sites in the ANKRD34B and ZIC1 candidate gene. OR (black filled circles) and 95% confidence intervals and the no risk OR = 1 line (dashed line) are presented. Corresponding p-values of logistic regression and covariate parameters of analyses are shown in Table 2.

2.5. Analysis of CpG-Specific Methylation in Paired Tumor-Adjacent and Tumor Tissue Samples Shows Heterogeneous Alterations

The CpG site-specific comparison of paired tumor and adN tissues demonstrated tumor-specific hypermethylation for all loci (Table 3). Mean differences of 6.2–11.4% in the relative methylation, corresponding to p-values of $3.38 \times 10^{-5}$–$1.46 \times 10^{-11}$, were obtained for the 10 analyzed candidate loci (Table 3).
Table 3. CpG site-specific statistical comparison of paired tumor adjacent normal and tumor tissue samples using the two-sided t-test.

| Region. | CpG | Mean | CI Low | CI High | p-Value | p-Value (Adj.) |
|---------|-----|------|--------|---------|---------|---------------|
| ANKRD34B | CG1 | 11.4 | 8.3    | 14.6    | $4.80 \times 10^{-11}$ | $1.44 \times 10^{-10}$ |
|         | CG2 | 11.9 | 8.8    | 15.0    | $2.90 \times 10^{-12}$ | $1.74 \times 10^{-11}$ |
|         | CG3 | 10.4 | 7.5    | 13.3    | $5.41 \times 10^{-11}$ | $1.44 \times 10^{-10}$ |
|         | CG4 | 11.1 | 8.3    | 13.9    | $2.09 \times 10^{-12}$ | $1.46 \times 10^{-11}$ |
|         | CG5 | 11.1 | 8.1    | 14.0    | $7.10 \times 10^{-12}$ | $3.55 \times 10^{-11}$ |
|         | CG6 | 10.5 | 7.7    | 13.4    | $1.89 \times 10^{-11}$ | $7.58 \times 10^{-11}$ |
|         | CG7 | 7.7  | 5.1    | 10.3    | $4.41 \times 10^{-08}$ | $4.41 \times 10^{-08}$ |
| ZIC1    | CG1 | 6.2  | 3.3    | 9.0     | $3.38 \times 10^{-05}$ | $3.38 \times 10^{-05}$ |
|         | CG2 | 8.4  | 5.8    | 11.1    | $3.93 \times 10^{-09}$ | $1.18 \times 10^{-08}$ |
|         | CG3 | 7.6  | 4.9    | 10.3    | $1.17 \times 10^{-07}$ | $2.35 \times 10^{-07}$ |

Abbreviations: Diff., difference; CI, 95% confidence interval; adj., holm adjustment for multiple testing.

A detailed comparison of CpG site-specific methylation values using a heatmap presentation of a cluster analysis demonstrated four stable patient clusters of similar size for both candidate genes (Figure 5). These included a large neutral cluster without substantial methylation changes (Cluster 1), two clusters with moderate and strong tumor-specific hypermethylation (Clusters 2 and 4), and a small cluster exhibiting hypomethylation.

2.6. Analysis of Human Cancer Cell Lines

Common cell line models of prostate, breast, urothelial, renal, and other cancers were used to estimate whether hypermethylation of ANKRD34B and ZIC1 can occur with relevant frequency in human tumors. Gene-wise averaged relative methylation levels superseding the values observed for primary normal cell controls of kidney (RPTEC), prostate (Prec), and breast (HMEC) tissues were found for at least half of the kidney,
prostate, urothelial, and breast cancer cell line models for both the ANKRD34B and ZIC1 candidate regions (Figure 6).

Figure 6. (A) ANKRD34B; (B) ZIC1. Analysis of candidate region methylation in various human tumor cell line models and controls. Designated human tumor cells were grouped according to tumor origins (RCC, renal cell cancer, CaP, prostate cancer, UTC, urothelial tumor cells, MCa, breast cancer and others).

3. Discussion

We recently described that candidate loci for age-dependent methylation can be identified by biometrical analysis of the TCGA-KIRC DNAme data using a subset of normal tumor-adjacent kidney tissues [11]. Here, we evaluated further candidate loci in ANKRD34B and ZIC1 for age-related methylation and their possible additional age-independent contribution to the risk of RCC development.

Analysis of the normal autopsy tissue cohort revealed a strong association of the methylation of each of the 10 CpG sites with age. Thus, from a statistical perspective, age could explain a maximum of 77% of methylation variance (R = 0.88) in the ZIC1–CG2 locus. This resembles the results we previously obtained for the analysis of age-dependent TBR1 methylation in normal autopsy tissues (R = 0.85) [11]. Moreover, 9 out of 10 ANKRD34B sites clearly had higher coefficients of correlation compared to loci reported previously to be usable for saliva-based determination of donor age [42].

Assessment of the annual increase in age-dependent methylation showed an approximately 60% higher value for the ZIC1–CG2 locus (0.26% annual methylation increase) compared to the ANKRD34B–CG1 site (0.16% annual methylation increase). Few data have been reported on the average annual increase in normal solid tissue methylation. Previous work found an annual methylation increase of 0.06% (SFRP1), 0.15% (RASSF1), and 0.25% (TBR1) [10,11,43]. Overall, these results clearly identified the ANKRD34B and ZIC1 regions as targets of age-related methylation in normal kidney cells, and our preliminary statistical model for predicting chronological age identified a subset of loci as possible contributors to methylation-based chronological age prediction in solid normal renal tissue (e.g., for forensic purposes). This could be of use for determining age in forensic tasks, considering the good post-mortem stability of kidney tissues for DNA-based measurements [44].

Notably, the analysis of age-dependent methylation in normal tumor-adjacent tissue samples revealed a substantial number of samples with methylation above the 99% predic-
tion interval, as defined by the regression analysis of normal autopsy tissue samples. Levels of DNAme resembled those detected in tumor tissues and are not reached in normal control tissues even within a 100-year lifetime. Independent CpG site-specific statistical analysis using logistic regression analysis considering age and sex as covariates also demonstrated significantly increased methylation levels at 90% of the measured CpG sites in ANKRD34B and ZIC1 in the high RCC-risk normal tissue group. Therefore, our results showed that additional age-independent methylation accelerators likely exist in a subset of normal tissues in the risk group. Moreover, with concurrent tumor-specific hypermethylation of loci, the corresponding CpG sites represent candidates for epigenetic renal cancer susceptibility.

Our cluster analysis of the individual DNAme of paired adN and tumor samples revealed stable groups of similar size for both candidate regions. A large sample cluster representing approximately half of the samples presented were without significant changes in DNAme, whereas two clusters were found with moderate and strong tumor-specific increases in ANKRD34B and ZIC1 methylation, supporting a possible contribution of alterations in RCC development. Taking into consideration that both regions demonstrate hypermethylation in a large number of cell line models of important human cancers, these findings conceivably have a broader relevance and, in the case of ZIC1, this has already been confirmed in the literature [18–22,32,33,35–38].

On the other hand, a small cluster apparently revealed tumor-specific hypomethylation of ANKRD34 and ZIC1 loci starting from considerably increased methylation in adN samples, although a further increase in the tumor samples would have been expected. However, pyrosequencing only provides the detection of sample average methylation levels and, therefore, may be limited when spatial and/or cellular heterogeneity likely affects the interpretation of DNAme in individual samples. An appropriate study design and methylation detection technique are required to demonstrate a possible epigenetic lineage of tumor cells, such as that indicated by a sequence of risk factor-increased methylation of ANKRD34B and/or ZIC1 in normal cells and a further increase in derived tumor cells.

Epigenetic cancer age-independent susceptibility in normal renal tissues was found previously for the SFRP1 region [10], but could not be detected in TBR1 loci, although both genes demonstrated clear age-dependent methylation. Thus, the newly identified ANKRD34B and ZIC1 cancer loci double the number of age-independent susceptibility loci detected in normal kidney tissue, and strengthen the hypothesis that more as yet unidentified loci may exist. The epigenetic cancer risk data obtained using normal solid target tissues are thin, and most EWASs have been focused on the analysis of surrogate material, using blood samples to a large extent [3].

The present study differs from approaches making use of methylation alteration detection in blood samples for the set-up of a tissue-independent determination of epigenetic age of individuals in one essential aspect. While different variants of such epigenetic clocks have been used for statistical risk assessment of a variety of malignant and non-malignant diseases through a comparison of real and epigenetic age, the informativity for cancer risk estimation could be limited, particularly when considering the known tissue specificity of DNAme [ibid]. Thus, our approach of using normal target tissue measurement for detecting DNAme-associated cancer risk clearly circumvents the principal difficulties associated with the measurement of surrogate tissues, bearing in mind that DNAme and accumulation is assumed to be largely tissue-specific [45,46].

Notably, the ideal approach of measuring normal target tissues at risk in a prospective study design has been reported using normal cervical cells for epigenetic cancer risk prediction, likely aided by the availability of normal cells in the clinical routine [47]. However, considering that normal renal cell DNAme detection can also be carried out in principle with urine samples [48], comparable approaches for RCC prediction seem to be possible—at least theoretically.

On the one hand, the use of normal high-risk samples derived from donors with proven malignancy means that the risk-event cancer has already occurred and, theoretically, false-positive results may be obtained by tumor cell contamination of normal target tissues.
On the other hand, RCC tumors normally present with a capsule that clearly separates the renal tumor mass from the normal tissues. Therefore, the gold standard surgical treatment includes laparoscopic partial resection of localized tumors, which is only possible because there are no reliable indications of the presence of extracapsular tumor cells. To the best of our knowledge, such histological evidence has not been described in the literature. Correspondingly, our histopathological evaluation of peritumoral samples, molecular analysis of CA9 tumor marker expression in adN tissues, and DNA quality of autopsy-based DNA isolation did not give any hint of either tumor cell contamination or the presence of technically associated artificial effects [10]. Moreover, the age-independent increase in normal tissue methylation was not associated with parameters of clinical aggression of the corresponding tumors, such as state of metastasis, disease progression, state of advanced disease, high-stage, or high-grade tumors (all \( p > 0.73 \), data not shown), which should be expected for the spread of tumor cells into surrounding normal tissue. Consequently, we consider the probability of false-positive detection of methylation in normal tumor-adjacent tissues to be extremely low.

Although the sparse functional data reported for \( \text{ANKRD34B} \) do not allow even hypothetical assumptions about possible causes or consequences of the DNAme of loci, a recent study collating blood and solid tissue-based EWASs aimed at investigating the effect of smoking as a lifestyle factor on DNAme identified \( \text{ZIC1} \) as a target in both solid human brain tissue and blood cells [39,40]. Future analyses of normal renal tissues that consider additional risk factors, such as cotinine levels in tissues and data about drug abuse, are required to systemize the search for further lifestyle factor-associated methylation that is relevant to RCC development.

## 4. Methods

### 4.1. In Silico Analysis for Candidate Identification

Candidate selection was carried out using the TCGA KIRC HM450K Illumina platform data as reported previously [11].

### 4.2. Primary Cells and Tumor Cell Lines

Analysis of primary cells and tumor cell line models was performed as described previously [11].

### 4.3. Study Design

We used a cross-sectional study design to analyze a possible relationship between DNAme of candidate loci and the age of tissue donors, each consisting of 214 normal renal autopsy and a maximum of 157 normal tumor-adjacent tissue measurements (Table 4). A case-control study comparing normal tumor-adjacent samples (cases) with normal autopsy samples (controls) was carried out to estimate the odds ratios associated with DNAme in candidate loci. Tumor-specific hypermethylation was investigated in 143 (\( \text{ANKRD34B} \)) and 125 (\( \text{ZIC1} \)) paired normal tumor-adjacent and tumor samples (Table 4).

### Table 4. Tissue characteristics of normal autopsy (N), tumor adjacent normal (adN) and tumor tissues (T).

| Tissue | Gene     | N   | adN  | adN/T  |
|--------|----------|-----|------|--------|
|        | ANKRD34B | 214 | 214  | 143    |
|        | ZIC1     | 157 | 145  | 125    |
| Age (y) | Median  | 61  | 60   | 65     |
|        | (min–max)| (0–98) | (0–99) | (35–91) |
| Sex (n) | female (%) | 77 (36.0) | 72 (33.6) | 53 (36.6) |
|        | male (%)  | 137 (64.0) | 142 (66.4) | 90 (62.9) |

Note that Total (n) of the cohort refers to the measurement of largely, but not perfectly, equal subsets of a larger cohort of 239 N samples. adN* samples represent a subset of adN samples with available paired tumor tissue measurements.
4.4. Analysis of DNA Methylation

Histological and molecular evaluation of tissue samples subjected to DNA extraction, conversion of DNA, primer design, and subsequent pyrosequencing has been described previously [11,49,50]. The primer sequences used for pyrosequencing (5’- 3’) of candidate loci were: ANKRD34B, GAGGGATAAGGATTGGAGGAGTTAAAG (forward), Biotin-ACCCAAAAAAACCAACAACTACTAAA (reverse), TGTAGTTGTGTGGGTGTAAAG (sequencing); ZIC1, AATAGGAGTGAGGAGATAGG (forward), Biotin-CCATTTCCTTTTCTCTCTCTTTAC (reverse), AGGAGATGGGT (sequencing). The candidate loci and CpG sites measured by pyrosequencing ANKRD34B (CG1-CG7) and ZIC1 (CG1-CG3) are summarized in Table 1. The genomic localization of measured and candidate CpG sites is presented in Figure 1.

4.5. Statistical Analysis

Age-dependent methylation of candidate loci was analyzed by CpG site-specific Pearson correlation analysis. Presentation of age-dependent methylation included the mean DNAme of the two candidate genes after linear regression and calculation of the 95% confidence interval for the regression line, as well as the 99% prediction channels. The case-control comparison of independent tissue samples was analyzed by logistic regression considering age and sex as covariates. Odds ratios and 95% confidence intervals are presented. Tumor-specific hypermethylation of paired normal and tumor tissue samples was analyzed by the two-sided paired t-test. The sample-specific DNAme of paired adN and tumor tissue samples was compared by unsupervised kmean clustering, presenting a consensus cluster after 100 bootstrap runs as a heatmap. Clusters exhibiting Jaccard coefficients >0.8 were considered stable clusters. All statistical calculations and presentations were done using R 3.6 [51].

5. Conclusions

Our study identified DNAme of ANKRD34 and ZIC1 as new cancer susceptibility loci for RCC development. Moreover, the loci represent targets for age-dependent methylation in solid normal kidney tissues, providing a possible contribution to chronological age determination by methylation detection in solid renal tissues.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23105327/s1.

Author Contributions: Conceptualization: J.S., I.P. and M.A.K.; methodology: J.S. and I.P.; DNA extraction, bisulfite treatment of DNA and methylation analyses: B.H. and T.H.; writing—original draft preparation, review and editing: J.S., I.P. and J.H.; visualization: J.S. and I.P.; statistical analysis: J.S.; selection, sampling of tissue: M.K. and J.H.; scientific discussion: J.S., M.K. and M.A.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethical board of Eberhard Karls University Tuebingen (Head Prof. Jaschonek) and the ethical board of Hanover Medical School (Head Prof. Engeli) under vote no. 128/2003V (2003) and 1213-2011 (2011/10/14). Autopsy tissue samples were obtained from the department of legal medicine (Head Prof. Klintschar). No objections were raised by the local ethics committee (Head Prof. Engeli) to the anonymous analyses of autopsy tissues.

Informed Consent Statement: Informed consent was obtained from all tumor-related subjects involved in the study.

Data Availability Statement: The anonymized datasets used and/or analyzed during the current study are available as supplementary materials.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Feinberg, A.P. Phenotypic plasticity and the epigenetics of human disease. *Nature* 2007, 447, 433–440. [CrossRef] [PubMed]

2. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. *Nat. Rev. Genet.* 2006, 7, 21–33. [CrossRef] [PubMed]

3. Widschwendter, M.; Jones, A.; Evans, I.; Reisel, D.; Sundstrom, K.; Steyerberg, E.W.; Vergouwe, Y.; Wegwarth, O.; Rebischek, F.G.; et al. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. *Nat. Rev. Clin. Oncol.* 2018, 15, 292–309. [CrossRef] [PubMed]

4. Kotecha, R.R.; Motzer, R.J.; Voss, M.H. Toward individualized therapy for metastatic renal cell carcinoma. *Nat. Rev. Clin. Oncol.* 2019, 16, 621–633. [CrossRef]

5. Pischon, T.; Lahmann, P.H.; Boeing, H.; Tjonneland, A.; Halkjaer, J.; Overvad, K.; Klipstein-Grobusch, K.; Linseisen, J.; Becker, N.; Trichopoulou, A.; et al. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int. J. Cancer* 2006, 118, 728–738. [CrossRef]

6. Hunt, J.D.; van der Hel, O.L.; McMillan, G.P.; Boffetta, P.; Brennan, P. Renal cell carcinoma in relation to cigarette smoking: Meta-analysis of 24 studies. *Int. J. Cancer* 2005, 114, 101–108. [CrossRef]

7. Mucci, L.A.; Hjelmborg, J.B.; Harris, J.R.; Czene, K.; Havelick, D.J.; Scheike, T.; Graff, R.E.; Holst, K.; Moller, S.; Unger, R.H.; et al. Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA* 2016, 315, 68–76. [CrossRef]

8. Joosten, S.C.; Smits, K.M.; Aarts, M.J.; Melotte, V.; Koch, A.; Tjan-Heijnen, V.C.; van Engeland, M. Epigenetics in renal cell cancer: Mechanisms and clinical applications. *Nat. Rev. Urol.* 2018, 15, 430–451. [CrossRef]

9. Wang, L.J.; Jin, H.C.; Wang, X.; Lam, E.K.; Zhang, J.B.; Liu, X.; Chan, F.K.; Si, J.M.; Sung, J.J. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. *Biochem. Biophys. Res. Commun.* 2009, 375, 21–33. [CrossRef] [PubMed]

10. Wang, L.J.; Zhan, B.; Wei, D.; Zhang, Z. Identification of Methylated Gene Biomarkers in Patients with Alzheimer’s Disease Based on Machine Learning. *BioMed Res. Int.* 2020, 2020, 8348149. [CrossRef]

11. Ren, J.; Zhang, B.; Wei, D.; Zhang, Z. Identification of Methylated Gene Biomarkers in Patients with Alzheimer’s Disease Based on Machine Learning. *BioMed Res. Int.* 2020, 2020, 8348149. [CrossRef]

12. Serth, J.; Peters, I.; Dubrowinska, N.; Reese, C.; Albrecht, K.; Klintschar, M.; Lafos, M.; Grote, A.; Becker, A.; Hennenlotter, J.; et al. Age-, tumor-, and metastatic tissue-associated DNA methylation of a T-box brain 1 locus in human kidney tissue. *Clin. Epigenetics* 2020, 12, 33. [CrossRef]

13. Al-Shaibi, N.; Ghosh, S.K. A novel phosphoprotein is induced during bone marrow commitment to dendritic cells. *Biochem. Biophys. Res. Commun.* 2004, 321, 26–30. [CrossRef]

14. Uhlen, M.; Fagerberg, L.; Hallstrom, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, A.; Kampf, C.; Sjostedt, E.; Asplund, A.; et al. Proteomics. Tissue-based map of the human proteome. *Science* 2015, 347, 1260419. [CrossRef]

15. Ren, J.; Zhang, B.; Wei, D.; Zhang, Z. Identification of Methylated Gene Biomarkers in Patients with Alzheimer’s Disease Based on Machine Learning. *BioMed Res. Int.* 2020, 2020, 8348149. [CrossRef]

16. Nikitina, A.S.; Sharova, E.I.; Danilenko, S.A.; Butusova, T.B.; Vasiliev, A.O.; Govorov, A.V.; Prilepskaya, E.A.; Pushkar, D.Y.; Kostryukova, E.S. Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients. *OncoTargets* 2018, 8, 32990–33001. [CrossRef]

17. Chahal, B.; Bellchambers, H.M.; Arkell, R.M. Zinc fingers of the cerebellum (Zic): Transcription factors and co-factors. *Int. J. Biochem. Cell Biol.* 2012, 44, 2065–2068. [CrossRef]

18. Gan, L.; Chen, S.; Zhong, J.; Wang, X.; Lam, E.K.; Liu, X.; Zhang, J.; Zhou, T.; Yu, J.; Si, J.; et al. ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. *PLoS ONE* 2011, 6, e16916. [CrossRef]

19. Wang, L.J.; Jin, H.C.; Wang, X.; Lam, E.K.; Zhang, J.B.; Liu, X.; Chan, F.K.; Si, J.M.; Sung, J.J. ZIC1 is downregulated through promoter hypermethylation in gastric cancer. *Biochem. Biophys. Res. Commun.* 2009, 379, 959–963. [CrossRef]

20. Hou, Y.; Chen, K.; Liao, R.; Li, Y.; Yang, H.; Gong, J. LINC01419-mediated epigenetic silencing of ZIC1 promotes metastasis in hepatocellular carcinoma through the PI3K/Akt signaling pathway. *Lab. Invest.* 2021, 101, 570–587. [CrossRef]

21. Wang, Y.Y.; Jiang, J.X.; Ma, H.; Han, J.; Sun, Z.Y.; Liu, Z.M.; Xu, Z.G. Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. *Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med.* 2014, 35, 7429–7433. [CrossRef]

22. Qiang, W.; Zhao, Y.; Yang, Q.; Liu, W.; Guan, H.; Lv, S.; Ji, M.; Shi, B.; Hou, P. ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a. *J. Clin. Endocrinol. Metab.* 2014, 99, E1163–E1172. [CrossRef]

23. Pourebrahim, R.; Van Dam, K.; Bauters, M.; De Wever, I.; Sciort, R.; Cassiman, J.J.; Teipar, S. ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. *FEBS Lett.* 2007, 581, 5122–5126. [CrossRef]

24. Cheng, Y.Y.; Kirschner, M.B.; Cheng, N.C.; Gattani, S.; Klebe, S.; Edelman, J.J.; Vallely, M.L.P.; McCaughan, B.C.; Jin, H.C.; van Zandwijk, N.; et al. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. *J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer* 2013, 8, 1317–1328. [CrossRef]

25. Baribault, C.; Ehrlich, K.C.; Ponnaluri, V.K.C.; Pradhan, S.; Lacey, M.; Ehrlich, M. Developmentally linked human DNA hypermethylation is associated with down-modulation, repression, and upregulation of transcription. *Epigenetics* 2018, 13, 275–289. [CrossRef]
26. Dick, S.; Verhoeof, L.; De Strooper, L.M.; Ciocanea-Teodorescu, I.; Wisman, G.B.A.; Meijer, C.J.; Bleeker, M.C.; Steenbergen, R.D.; Heideman, D.A. Evaluation of six methylation markers derived from genome-wide screens for detection of cervical precancer and cancer. *Epigenomics* 2020, 12, 1569–1578. [CrossRef]

27. Verhoeof, L.; Bleeker, M.C.G.; Polman, N.; Steenbergen, R.D.M.; Meijer, C.; Melchers, W.J.G.; Bekkers, R.L.; Molijn, A.C.; Quint, W.G.; van Kempen, F.; et al. Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: Results from a Dutch primary HPV-based screening cohort. *Int. J. Cancer* 2022, 150, 440–449. [CrossRef]

28. Verlaat, W.; Snijders, P.J.; Novianti, P.W.; Wilting, S.M.; De Strooper, L.M.A.; Trooskens, G.; Vandersmissen, J.; van Criekinge, W.; Wisman, G.B.A.; Meijer, C.; et al. Genome-wide DNA Methylation Profiling Reveals Methylation Markers Associated with 3q Gain for Detection of Cervical Precancer and Cancer. *Clin. Cancer Res.* 2017, 23, 3813–3822. [CrossRef]

29. van den Helder, R.; Weyer, B.M.M.; van Trommel, N.E.; van Splunter, A.P.; Mont, C.H.; Kasius, J.C.; Bleeker, M.C.G.; Steenbergen, R.D.M. Non-invasive detection of endometrial cancer markers by DNA methylation analysis in urine. *Clin. Epigenetics* 2020, 12, 165. [CrossRef]

30. Lin, Z.; Luo, M.; Chen, X.; He, X.; Qian, Y.; Lai, S.; Si, J.; Chen, S. Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation as a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions. *J. Cancer* 2017, 8, 1038–1044. [CrossRef] [PubMed]

31. Chen, X.; Lin, Z.; Xue, M.; Si, J.; Chen, S. Zic1 Promoter Hypomethylation in Plasma DNA Is a Potential Biomarker for Gastric Cancer and Intraepithelial Neoplasia. *PloS ONE* 2015, 10, e0133906. [CrossRef] [PubMed]

32. van den Helder, R.; van Trommel, N.E.; van Splunter, A.P.; Lissenberg-Witte, B.I.; Bleeker, M.C.G.; Steenbergen, R.D.M. Methylation analysis in urine fractions for optimal CIN3 and cervical cancer detection. *Pallaviomavirus Res.* 2020, 9, 100193. [CrossRef] [PubMed]

33. van der Zee, R.P.; van Noesel, C.J.M.; Martin, I.; Ter Braak, T.J.; Heideman, D.A.M.; de Vries, H.J.C.; Prins, J.M.; Steenbergen, R.D.M. DNA methylation markers have universal prognostic value for anal cancer risk in HIV-negative and HIV-positive individuals. *Mol. Oncol.* 2021, 15, 3024–3036. [CrossRef] [PubMed]

34. Rodriguez-Rodero, S.; Fernandez, A.F.; Fernandez-Morera, J.L.; Castro-Santos, P.; Bayon, G.F.; Ferrero, C.; Urdinguio, R.G.; Gonzalez-Marquez, R.; Suarez, C.; Fernandez-Vega, I.; et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. *J. Clin. Endocrinol. Metab.* 2013, 98, 2811–2821. [CrossRef]

35. Paluszczak, J.; Wisniewska, D.; Kostrzewska-Poczekaj, M.; Kiwerska, K.; Grenman, R.; Mielcarek-Kuchta, D.; Jarmuz-Szymczak, J. Prognostic significance of the methylation of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas. *Clin. Oral Investig.* 2017, 21, 1777–1788. [CrossRef]

36. Kitchen, M.O.; Bryan, R.T.; Haworth, K.E.; Emes, R.D.; Luscombe, A.; Gommersall, L.; Cheng, K.K.; Zabaleta, J.; Delgado, A.; Fernandez-Morera, J.L.; Bayon, G.F.; Ferrero, C.; Urdinguio, R.G.; Rodriguez-Rodero, S.; Fernandez, A.F.; Fernandez-Morera, J.L.; Castro-Santos, P.; Bayon, G.F.; Ferrero, C.; Urdinguio, R.G.; Gonzalez-Marquez, R.; Suarez, C.; Fernandez-Vega, I.; et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. *J. Clin. Endocrinol. Metab.* 2013, 98, 2811–2821. [CrossRef] [PubMed]

37. Schneider, B.G.; Mera, R.; Piazuelo, M.B.; Bravo, J.C.; Aslibekyan, S.; et al. Epigenetic Signatures of Cigarette Smoking. *Circulation. Cardiovasc. Genet.* 2016, 9, 118–125. [CrossRef]

38. Huang, R.L.; Gu, F.; Kirma, N.B.; Ruan, J.; Chen, C.L.; Wang, H.C.; Liao, Y.P.; Chang, C.C.; Yu, M.H.; Pilrose, J.M.; et al. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. *Epigenetics* 2013, 8, 624–634. [CrossRef]

39. Joeannes, R.; Just, A.C.; Marioni, R.E.; Pilling, I.C.; Reynolds, L.M.; Mandaviliya, P.R.U.; Guan, W.; Xu, T.; Elks, C.E.; Aslibekyan, S.; et al. Epigenetic Signatures of Cigarette Smoking. *Circulation. Cardiovasc. Genet.* 2016, 9, 436–447. [CrossRef]

40. Markunas, C.A.; Semić, S.A.; Quach, B.C.; Tao, R.; Deep-Soboslay, A.; Carsnes, M.U.; Bierut, L.J.; Hyde, T.M.; Kleinman, J.E.; Johnson, E.O.; et al. Genome-wide DNA methylation differences in nucleus accumbens of smokers vs. nonsmokers. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2021, 46, 554–560. [CrossRef]

41. Zheng, Y.; Huang, G.; Silva, T.C.; Yang, Q.; Jiang, Y.Y.; Koefler, H.P.; Lin, D.C.; Berman, B.P. A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycrom target genes. *Nat. Commun.* 2021, 12, 2485. [CrossRef]

42. Hong, S.R.; Jung, S.E.; Lee, E.H.; Shin, K.J.; Yang, W.I.; Lee, H.Y. DNA methylation-based age prediction from saliva: High age predictability by combination of 7 CpG markers. *Forensic Sci. Int. Genet.* 2017, 29, 118–125. [CrossRef]

43. Peters, I.; Remhet, K.; Wilke, N.; Cuczyk, M.; Hennenlotter, J.; Eilers, T.; Machtens, S.; Jonas, U.; Serth, J. RASSF1A promoter methylation as exception. *Epigenetics Chromatin* 2018, 11, 25. [CrossRef]

44. Peters, I.; Remhet, K.; Wilke, N.; Cuczyk, M.; Hennenlotter, J.; Eilers, T.; Machtens, S.; Jonas, U.; Serth, J. RASSF1A promoter methylation as exception. *Epigenetics Chromatin* 2018, 11, 25. [CrossRef]

45. Teschendorff, A.E.; Jones, A.; Fiegel, H.; Sargent, A.; Zhuang, J.J.; Kitchener, H.C.; Widschwendter, M. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. *Clin. Epigenetics* 2013, 23, 1067–10163. [CrossRef] [PubMed]

46. Huang, R.L.; Gu, F.; Kirma, N.B.; Ruan, J.; Chen, C.L.; Wang, H.C.; Liao, Y.P.; Chang, C.C.; Yu, M.H.; Pilrose, J.M.; et al. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. *Epigenetics* 2013, 8, 624–634. [CrossRef]

47. Joeannes, R.; Just, A.C.; Marioni, R.E.; Pilling, I.C.; Reynolds, L.M.; Mandaviliya, P.R.U.; Guan, W.; Xu, T.; Elks, C.E.; Aslibekyan, S.; et al. Epigenetic Signatures of Cigarette Smoking. *Circulation. Cardiovasc. Genet.* 2016, 9, 436–447. [CrossRef]

48. Markunas, C.A.; Semić, S.A.; Quach, B.C.; Tao, R.; Deep-Soboslay, A.; Carsnes, M.U.; Bierut, L.J.; Hyde, T.M.; Kleinman, J.E.; Johnson, E.O.; et al. Genome-wide DNA methylation differences in nucleus accumbens of smokers vs. nonsmokers. *Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol.* 2021, 46, 554–560. [CrossRef]

49. Zheng, Y.; Huang, G.; Silva, T.C.; Yang, Q.; Jiang, Y.Y.; Koefler, H.P.; Lin, D.C.; Berman, B.P. A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycrom target genes. *Nat. Commun.* 2021, 12, 2485. [CrossRef] [PubMed]
48. Marumo, T.; Hoshino, J.; Kawarazaki, W.; Nishimoto, M.; Ayuzawa, N.; Hirohama, D.; Yamanouchi, M.; Ubara, Y.; Okaneya, T.; Fujii, T.; et al. Methylation pattern of urinary DNA as a marker of kidney function decline in diabetes. *BMJ Open Diabetes Res. Care* 2020, 8, e001501. [CrossRef]

49. Gebauer, K.; Peters, I.; Dubrowinskaja, N.; Hennenlotter, J.; Abbas, M.; Scherer, R.; Tezval, H.; Merseburger, A.S.; Stenzl, A.; Kuczyk, M.A.; et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. *Br. J. Cancer* 2013, 108, 131–138. [CrossRef]

50. Tezval, H.; Dubrowinskaja, N.; Peters, I.; Reese, C.; Serth, K.; Atschekzei, F.; Hennenlotter, J.; Stenzl, A.; Kuczyk, M.A.; Serth, J. Tumor Specific Epigenetic Silencing of Corticotropin Releasing Hormone -Binding Protein in Renal Cell Carcinoma: Association of Hypermethylation and Metastasis. *PLoS ONE* 2016, 11, e0163873. [CrossRef]

51. R Core Team. *R: A Language and Environment for Statistical Computing*; R Foundation for Statistical Computing: Vienna, Austria, 2021. Available online: https://www.R-project.org/ (accessed on 21 March 2022).